The best hs-CRP level for longevity is below 1.0 mg/L, the standard low cardiovascular risk category, with below 0.2 mg/L treated as an optimized result. hs-CRP (high-sensitivity C-reactive protein) is a blood marker for low-grade systemic inflammation, produced by the liver in response to inflammatory signaling from throughout the body. Unlike acute inflammation you can feel, a swollen ankle, a sore throat, the chronic, low-grade inflammation hs-CRP detects typically produces no symptoms at all, while still being one of the more consequential independent predictors of cardiovascular risk identified in the last several decades of medical research, and one that changed how seriously cardiology takes inflammation as a distinct, targetable risk factor.
- Below 1.0 mg/L is considered low cardiovascular risk, below 0.2 mg/L is an optimized, excellent result.
- The landmark JUPITER trial found elevated hs-CRP predicted cardiovascular risk even in people with normal cholesterol.
- hs-CRP and standard CRP measure the same molecule, but hs-CRP can detect the far lower concentrations relevant to cardiovascular risk.
- A recent infection or injury can transiently spike hs-CRP by 100x or more, unrelated to your baseline cardiovascular risk.
How CRP actually works
C-reactive protein is produced by the liver as part of the acute phase response, the coordinated set of changes your body makes to inflammation, infection or tissue injury.
When immune cells detect a problem anywhere in the body, they release signalling molecules, particularly interleukin-6. That travels to the liver and triggers a sharp rise in CRP production, sometimes a thousand-fold within 24 to 48 hours during a significant infection or injury.
That makes CRP one of the fastest-responding markers in the whole system, rising well before other inflammatory changes become detectable.
The same system also responds to much smaller, chronic sources: low-grade inflammation from excess visceral fat, from atherosclerotic plaque itself, from gum disease, and from other sustained low-level processes.
The "high-sensitivity" part refers to the assay's ability to detect those smaller concentrations reliably, the ones relevant to long-term cardiovascular risk, rather than only the large spikes a standard CRP test was designed to catch.
Without that sensitivity, someone with low cardiovascular-relevant inflammation and someone with meaningfully elevated chronic inflammation would look identical.
Inflammation is causally involved in atherosclerosis. That is not in question, and the trials targeting inflammatory pathways support it. What the genetic evidence shows is that CRP itself is a marker of that process rather than a driver of it.
Mendelian randomisation studies find that variants in the CRP gene which raise CRP levels do not increase the risk of coronary artery disease or stroke. Studies of the interleukin-6 receptor gene find the opposite: genetically reduced IL-6 signalling is causally linked to lower coronary artery disease risk. The causal signal sits upstream of CRP, in IL-6 signalling. None of this weakens the case for measuring hs-CRP. A marker that reliably reflects a causal process is still worth tracking. It does mean CRP is unlikely to be a useful treatment target in its own right, and the genetic evidence argues against it specifically.
What counts as a good hs-CRP level?
Cardiovascular risk categories, measured in mg/L, based on widely-used clinical cutoffs:
| Category | hs-CRP |
|---|---|
| Low risk | Below 1.0 mg/L |
| Average risk | 1.0 – 3.0 mg/L |
| High risk | Above 3.0 mg/L |
Cut-offs from the AHA/CDC statement on markers of inflammation, Pearson et al., Circulation, 2003.
Within the low-risk band, optimized percentile targets go further:
| Tier | hs-CRP |
|---|---|
| Top 10% | 0.5 – 1.0 mg/L |
| Top 5% | 0.2 – 0.5 mg/L |
| Top 1% | Below 0.2 mg/L |
These bands are Longevity Coach IQ percentile tiers, not diagnostic thresholds.
Above 10 mg/L is generally considered to indicate acute inflammation, an active infection, recent injury, or a flare of a chronic inflammatory condition, rather than reflecting baseline cardiovascular risk, and is typically excluded from cardiovascular risk interpretation until a repeat test once the acute cause has resolved and the person feels genuinely back to their normal baseline.
hs-CRP vs. standard CRP
Standard CRP and hs-CRP measure the same molecule. The difference is entirely in the assay's sensitivity and the range it reliably detects.
A standard CRP test was developed to diagnose acute conditions: infections, sepsis, inflammatory flares. It isn't precise enough at the low end to separate someone with excellent cardiovascular-relevant inflammation from someone meaningfully elevated. Both would simply read as normal.
| Standard CRP | hs-CRP | |
|---|---|---|
| Detection range | Roughly 10-1000 mg/L | Roughly 0.2-10 mg/L |
| Designed to detect | Acute infection, injury, inflammatory flares | Low-grade chronic inflammation |
| Cardiovascular risk use | Not sensitive enough | Standard for CV risk assessment |
| When each is ordered | Suspected acute infection or inflammatory disease | Cardiovascular risk screening |
Comparison of assay range and clinical use for the two versions of the same test.
If you've had a "CRP" test as part of a general checkup without specifying hs-CRP, it's worth confirming which version was actually run, since a standard CRP reading in the "normal" acute-illness sense doesn't necessarily rule out the kind of low-grade chronic elevation hs-CRP is specifically designed to catch.
hs-CRP interpreter
Enter your result. Retest when well and rested, since a recent infection or hard session can raise this substantially.
The JUPITER trial and why hs-CRP is taken seriously
The JUPITER trial is the study most responsible for hs-CRP's current standing in cardiovascular medicine.
It enrolled people with normal LDL cholesterol and elevated hs-CRP, a group standard risk assessment would have called low-risk on cholesterol alone. Statin treatment in that group produced a substantial reduction in cardiovascular events. Direct evidence that hs-CRP was identifying real, actionable risk that cholesterol was missing.
That mattered beyond supporting statin use in a new population. It was some of the clearest evidence that inflammation is an independent contributor to cardiovascular disease, not a passive marker correlating with risk for unrelated reasons.
Which is why hs-CRP sits alongside ApoB and blood pressure as its own signal, rather than being treated as a secondary test duplicating information already captured.
Since JUPITER, later research has refined the picture further, including trials targeting inflammatory pathways directly with anti-inflammatory medications rather than statins. Inflammation looks like a distinct, targetable contributor, not a downstream consequence of cholesterol that resolves once cholesterol is controlled. What CANTOS targeted was interleukin-1 beta, upstream of both IL-6 and CRP, which is consistent with inflammation being causal and CRP being the readout rather than the mechanism.
What makes hs-CRP spike
Acute causes produce the largest and fastest changes. Infections, injuries, surgery and flares of autoimmune conditions can raise hs-CRP a hundred-fold within a day or two. Those values say nothing about baseline cardiovascular risk and resolve once the cause does.
Which is why a single elevated reading, especially a very high one, shouldn't be read as cardiovascular risk information until an acute cause is ruled out. Something as minor as a recent cold or a dental procedure a few days earlier shifts the number meaningfully.
Chronic, lower-magnitude elevation is the part relevant to cardiovascular risk, and it has a different set of contributors. Excess visceral fat, smoking, chronic gum disease, poorly controlled blood sugar, chronic stress and poor sleep have all been linked to persistently raised hs-CRP.
Age brings a gradual rise in baseline inflammation too, sometimes called inflammaging. It contributes to multiple age-related conditions rather than cardiovascular disease alone, and it is why some rise over a lifetime is common even in people who stay otherwise healthy.
How to lower hs-CRP
Because chronic hs-CRP elevation is tied to several different contributors, the most effective approach usually addresses several at once rather than a single lever. Weight loss, particularly visceral fat reduction, tends to produce some of the largest measurable reductions in chronically elevated hs-CRP, given how directly visceral fat itself contributes to inflammatory signaling, sometimes producing meaningful reductions within just a few months of sustained effort.
Aerobic exercise and sleep
Regular aerobic exercise has anti-inflammatory effects independent of weight change, moderate, consistent exercise appears to have a more favorable effect on inflammation than either complete inactivity or very high volumes of intense training without adequate recovery. Improved sleep quality and duration are linked to lower baseline inflammation as well, poor sleep specifically activates inflammatory pathways in ways that show up measurably in markers like hs-CRP.
Diet pattern, gum disease and smoking
Dietary patterns rich in anti-inflammatory foods, particularly the polyphenol-rich fruits and vegetables, fatty fish, and olive oil characteristic of Mediterranean-style eating patterns, have shown measurable hs-CRP reductions in research, while diets high in refined carbohydrates and processed food are associated with higher baseline inflammation. Addressing gum disease and quitting smoking, both genuine chronic inflammatory contributors in their own right, round out the most evidence-backed levers currently available for someone working to lower a chronically elevated reading.
Limitations
hs-CRP is deliberately non-specific. It detects that inflammation is present somewhere, not where or why.
That is both its strength and its limit. It captures a broad range of chronic contributors in one number, and it cannot separate cardiovascular-relevant inflammation from a minor infection you had forgotten about.
So acute causes get ruled out first, and a trend measured across several occasions when you are well beats a single reading taken without context.
It is one piece of a broader picture, best read alongside ApoB, blood pressure and the other established markers rather than as a verdict on its own.
Don't retest too soon after an illness either. It can stay elevated for days to weeks after the cause has resolved, well after someone would call themselves recovered.
Common misconceptions
"A high hs-CRP always means high cardiovascular risk." A high reading needs context, a recent cold, minor injury, or dental work can spike it substantially without reflecting any change in cardiovascular risk. Retesting once any obvious acute cause has resolved is the right next step before drawing conclusions, ideally waiting at least a couple of weeks after symptoms have fully cleared.
"hs-CRP measures general 'inflammation in the body' in a way I can just feel." The chronic, low-grade inflammation relevant to cardiovascular risk is precisely the kind that produces no symptoms. That is why it needs a blood test rather than a judgement about how you feel. Someone can feel completely healthy while carrying meaningfully elevated inflammation.
"Anti-inflammatory supplements are the best way to lower it." The evidence for the lifestyle levers above, weight, exercise, sleep and diet pattern, is stronger and more consistent than for most supplements marketed at this. Prioritise those before expecting a capsule to do the work.
"If my cholesterol is fine, I don't need to worry about hs-CRP." That is exactly the population JUPITER studied, and exactly where it found previously invisible risk. Normal cholesterol does not mean inflammation-related risk is normal. The two markers capture different pieces of the picture.
How to test hs-CRP without misreading it
Consumer health guidance rarely mentions hs-CRP, or treats it as an obscure specialist test. It’s neither. It bridges body composition and cardiovascular health, since visceral fat is a major driver of chronic inflammation, which makes it a useful signal that body composition work is translating into metabolic improvement.
Test when you aren’t ill or recently injured. If it comes back elevated, rule out an acute cause before assuming it reflects chronic inflammation. That single caveat accounts for most misread results.
If body composition is your current focus, expect hs-CRP to improve as a by-product. Retest a few months after a meaningful change rather than treating it as a one-time check.
The app itself tracks hs-CRP alongside your body composition and cardiovascular scores, showing whether your progress is translating into lower inflammation.
Sources
Visceral fat reduction
Key references for the claims on this page. Where a figure is attributed to a specific study or body, it is named here.
- Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER). New England Journal of Medicine, 2008;359(21):2195-2207. The JUPITER trial. DOI
- Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease (CANTOS). New England Journal of Medicine, 2017;377(12):1119-1131. The trial targeting inflammation directly rather than through statins, referenced above. DOI
- Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. Circulation, 2003;107(3):499-511. The AHA/CDC statement establishing the low, average and high risk cut-offs used above. DOI
- Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. The Lancet, 2010;375(9709):132-140. An individual participant meta-analysis of 160,309 people without a history of vascular disease, and the largest assessment of the association between CRP concentration and vascular risk. DOI
- Fontana L, Eagon JC, Trujillo ME, et al. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes, 2007;56(4):1010-1013. The basis for visceral adipose tissue secreting IL-6 and contributing to systemic inflammatory load. DOI
- Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. The Lancet, 2012;379(9822):1214–1224. The genetic evidence that the causal signal sits in IL-6 signalling rather than in CRP itself.
Frequently asked
What is the best hs-CRP level for longevity?
Below 1.0 mg/L is the standard low cardiovascular risk category, and below 0.2 mg/L is the optimized result Longevity Coach IQ treats as exceptional. One caution: a single elevated reading after infection, injury or a hard training session reflects that event rather than chronic inflammation, so retest before drawing conclusions.
What is hs-CRP?
A blood marker for low-grade systemic inflammation, produced by the liver, more sensitive than standard CRP for detecting the subtle inflammation linked to cardiovascular risk.
What is a good hs-CRP level?
Below 1.0 mg/L is low cardiovascular risk. Below 0.5 mg/L is strong, below 0.2 mg/L is an optimized, excellent result.
Why is hs-CRP taken so seriously?
The JUPITER trial found elevated hs-CRP predicted cardiovascular risk even with normal cholesterol, and that treating it reduced cardiovascular events.
Can a cold or minor illness affect my hs-CRP test?
Yes, significantly, acute illness can spike hs-CRP 100-fold or more. Wait until you've fully recovered before testing for cardiovascular risk purposes.
How often should hs-CRP be tested?
Once or twice a year is reasonable for general cardiovascular risk screening in someone healthy, more often if actively working to lower a chronically elevated result and tracking progress.